MAP4K4: A Protein Targeted for Drug Treatment (G9448)

Target Name: MAP4K4

NCBI ID: G9448

MAP4K4

MAP4K4: A Protein Targeted for Drug Treatment

MAP4K4 (MAPK4 variant 4) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and muscles. It is a member of the MAPK4 family of proteins, which are known for their role in cell signaling pathways.

MAP4K4 is involved in a number of different processes in the body, including cell growth, differentiation, and survival. It has been shown to play a role in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Due to its involvement in so many different processes in the body, MAP4K4 has also been identified as a potential drug target. Researchers are studying the potential benefits and risks of targeting MAP4K4 in order to treat a variety of diseases.

One of the main advantages of targeting MAP4K4 is its potential to act as a biomarker. By studying the levels of MAP4K4 in different tissues and cells, researchers can monitor the effectiveness of treatments and identify potential biomarkers for disease. This can be especially important for diseases that are difficult to diagnose or treat, as it can help doctors to understand how the body is responding to different interventions.

Another potential advantage of targeting MAP4K4 is its role in cell signaling pathways. MAP4K4 is involved in a number of different signaling pathways, including the TGF-β pathway, the PI3K/Akt pathway, and the NF-kappa-B pathway. By inhibiting these pathways, researchers can target MAP4K4 and reduce the activity of this protein. This can be a useful way to treat diseases that are caused by the activity of these signaling pathways, such as cancer and neurodegenerative diseases.

Targeting MAP4K4 has also been shown to be effective in treating certain neurodegenerative diseases. For example, a study published in the journal Nature Medicine in 2018 found that inhibiting MAP4K4 using a small molecule inhibitor was effective in treating amyotrophic lateral sclerosis (ALS) in mice. The researchers noted that this approach could be a promising new treatment for ALS, as it targets a key protein involved in the disease.

In addition to its potential as a drug target, MAP4K4 is also of interest to researchers because of its role in cell signaling pathways. By studying the mechanisms behind its function, researchers can gain insights into how signaling pathways work in different cells and tissues. This knowledge can be useful for the development of new treatments and therapies.

Overall, MAP4K4 is a protein that has the potential to be a drug target for a variety of diseases. Its involvement in cell signaling pathways makes it an attractive target for researchers to study, and its potential as a biomarker and therapeutic target makes it an important area of research. Further studies are needed to fully understand the role of MAP4K4 in disease and to develop effective treatments.

Protein Name: Mitogen-activated Protein Kinase Kinase Kinase Kinase 4

Functions: Serine/threonine kinase that may play a role in the response to environmental stress and cytokines such as TNF-alpha. Appears to act upstream of the JUN N-terminal pathway. Phosphorylates SMAD1 on Thr-322

The "MAP4K4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAP4K4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets